Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer (Q35194754)
scientific article
Language:
(P31) (Q13442814)
(P304) 626-630
(P407) (Q1860)
(P433) 3
(P478) 78
(P577) Monday, July 18, 2011
(P921) (Q42824440)
(Q6934595)
(Q27139829)
(Q181257)
(P1433) (Q7900884)
(P1476) "Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer" (language: en)
(P2093) William K Oh
Matthew D Galsky
Walter M Stadler
Sandy Srinivas
Franklin Chu
Glenn Bubley
J Goddard
Joi Dunbar
Robert W Ross
(P2860) (Q24596926)
(Q34578443)
(Q37566640)
(Q34898930)
(Q28276567)
(Q35469572)
(Q36681221)
(Q35127277)
(Q28272747)
(Q33235187)
(Q40425901)
(Q35565240)
(Q42649187)
(Q33767866)
(Q41615181)
(Q33599964)
(Q27860985)
(Q34720809)
(Q46412217)
(Q29619905)
(Q37055392)
(Q40092018)
(Q40253707)
(Q40355248)
(Q46551678)
(Q43990059)
(Q79297587)
other details
description scientific article

External Links